Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

About this update from Xilio Therapeutics, Inc.

WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Ben Harshbarger as chief legal officer. "Ben is a proven leader, with deep legal and strategic experience across all stages of biotechnology companies," said René Russo, Pharm.D., president and chief executive officer of Xilio. "He joins our leadership team at an important time at Xilio, as we advance our pipeline of next-generation, multi-specific I-O therapies toward the clinic, including XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, and multiple masked T-cell engagers." "Xilio has built an impressive pipeline leveraging its clinically-validated masking technology, and I am excited to work alongside the team to help drive its strategic and operational goals and advance its promising pipeline of masked multi-specific I-O therapies," said Mr. Harshbarger. Ben Harshbarger Mr. Harshbarger brings over 20 years of executive leadership and legal expertise within the biopharmaceutical industry. Most recently, he served as chief legal officer at Astria Therapeutics, Inc. until its acquisition by BioCryst Pharmaceuticals, Inc. At Astria, Mr. Harshbarger served on the leadership team and helped lead strategic and operational initiatives, including the company's transition from Catabasis Pharmaceuticals, Inc. to Astria, its growth from a pre-clinical organization to a late-stage clinical company and its acquisition. Prior to Astria, he served as interim chief executive officer and general counsel at Novelion Therapeutics Inc. and as general counsel at Aegerion Pharmaceuticals, Inc., which was a subsidiary of Novelion. Earlier in his career, he served in legal roles of increasing responsibility at Cubist Pharmaceuticals, Inc., ViaCell, Inc., and Biogen, Inc. Mr. Harshbarger received his B.A. in political science from the University of Richmond and his J.D. from Boston College Law School. About Xilio Therapeutics Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Leveraging our cl...

View stock analysis, news, and events for Xilio Therapeutics, Inc.